CS
CGEM icon

Credit Suisse’s Cullinan Oncology CGEM Stock Holding History

Credit Suisse’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$780K Buy
45,755
+2,853
+7% +$44.1K ﹤0.01% 2408
2023
Q4 		$437K Buy
42,902
+23,423
+120% +$208K ﹤0.01% 2789
2023
Q3 		$176K Sell
19,479
-629
-3% -$6.55K ﹤0.01% 3049
2023
Q2 		$216K Buy
20,108
+9,358
+87% +$99.4K ﹤0.01% 3079
2023
Q1 		$110K Buy
10,750
+3
+0% +$33 ﹤0.01% 3199
2022
Q4 		$113K Buy
10,747
+184
+2% +$2.23K ﹤0.01% 3311
2022
Q3 		$135K Buy
10,563
+144
+1% +$1.94K ﹤0.01% 3361
2022
Q2 		$134K Sell
10,419
-1,970
-16% -$22.3K ﹤0.01% 3461
2022
Q1 		$131K Sell
12,389
-798
-6% -$10.8K ﹤0.01% 3455
2021
Q4 		$204K Buy
13,187
+3,653
+38% +$72.9K ﹤0.01% 4265
2021
Q3 		$215K Buy
9,534
+503
+6% +$13.4K ﹤0.01% 4207
2021
Q2 		$233K Buy
+9,031
New +$278K ﹤0.01% 4218

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Credit Suisse's CGEM Position: Q1 2024 in Review

Credit Suisse increased its Cullinan Oncology (CGEM) stake by 6.7% in Q1 2024, buying an estimated $44.1K and bringing the position to 45,755 shares worth $780K. The position accounts for ﹤0.01% of the portfolio, ranked #2408.

Credit Suisse first reported a position in CGEM in Q2 2021 and has held it in 12 quarters since. 113 funds tracked by Wall St. Rank hold CGEM as of Q1 2024.

  • Credit Suisse held 45,755 shares of Cullinan Oncology worth $780K as of Q1 2024.
  • Credit Suisse bought 2,853 Cullinan Oncology shares in Q1 2024, an estimated $44.1K.
  • Cullinan Oncology made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2408 holding.
  • Credit Suisse first reported a position in Cullinan Oncology in Q2 2021 and has held it in 12 quarters since.
  • 113 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.